JLTS
2021-03-12
...
Pfizer to exceed 2021 vaccine production target by as much as 20%, CEO says
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":328974606,"tweetId":"328974606","gmtCreate":1615484067105,"gmtModify":1703489871510,"author":{"id":3575002815051060,"idStr":"3575002815051060","authorId":3575002815051060,"authorIdStr":"3575002815051060","name":"JLTS","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>...</p></body></html>","htmlText":"<html><head></head><body><p>...</p></body></html>","text":"...","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/328974606","repostId":2118933190,"repostType":2,"repost":{"id":"2118933190","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615482033,"share":"https://www.laohu8.com/m/news/2118933190?lang=&edition=full","pubTime":"2021-03-12 01:00","market":"us","language":"en","title":"Pfizer to exceed 2021 vaccine production target by as much as 20%, CEO says","url":"https://stock-news.laohu8.com/highlight/detail?id=2118933190","media":"Reuters","summary":"By Michael Erman NEW YORK, March 11 (Reuters) - Pfizer Inc and BioNTech SE will exceed their","content":"<html><body><p>By Michael Erman</p><p> NEW YORK, March 11 (Reuters) - Pfizer Inc and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday.</p><p> \"We will exceed clearly, this year, the 2 billion doses,\" Bourla said in an interview.</p><p> By the fourth quarter, the companies will be at a 3 billion dose a year run rate, and should be able to produce that much next year, he added.</p><p> Bourla said the company expects to be able to meet its commitment of supplying 120 million doses of its vaccine to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks.</p><p> \"Those have already been manufactured\" and are currently being tested for quality, he said. </p><p> \"Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don't fail,\" he said. </p><p> (Reporting by Michael Erman Editing by Bill Berkrot)</p><p>((michael.erman@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to exceed 2021 vaccine production target by as much as 20%, CEO says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to exceed 2021 vaccine production target by as much as 20%, CEO says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-12 01:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>By Michael Erman</p><p> NEW YORK, March 11 (Reuters) - Pfizer Inc and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday.</p><p> \"We will exceed clearly, this year, the 2 billion doses,\" Bourla said in an interview.</p><p> By the fourth quarter, the companies will be at a 3 billion dose a year run rate, and should be able to produce that much next year, he added.</p><p> Bourla said the company expects to be able to meet its commitment of supplying 120 million doses of its vaccine to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks.</p><p> \"Those have already been manufactured\" and are currently being tested for quality, he said. </p><p> \"Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don't fail,\" he said. </p><p> (Reporting by Michael Erman Editing by Bill Berkrot)</p><p>((michael.erman@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2118933190","content_text":"By Michael Erman NEW YORK, March 11 (Reuters) - Pfizer Inc and BioNTech SE will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday. \"We will exceed clearly, this year, the 2 billion doses,\" Bourla said in an interview. By the fourth quarter, the companies will be at a 3 billion dose a year run rate, and should be able to produce that much next year, he added. Bourla said the company expects to be able to meet its commitment of supplying 120 million doses of its vaccine to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks. \"Those have already been manufactured\" and are currently being tested for quality, he said. \"Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don't fail,\" he said. (Reporting by Michael Erman Editing by Bill Berkrot)((michael.erman@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":28,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/328974606"}
精彩评论